title: The effect of antenatal phenobarbital therapy on neonatal intracranial hemorrhage in preterm infants.
abstract: BACKGROUND
  The administration of phenobarbital to pregnant women before delivery has been thought to decrease the frequency of intracranial hemorrhage in preterm infants. To evaluate this potential neuroprotective therapy further, we determined the effect of antenatal administration of phenobarbital on the frequency of neonatal intracranial hemorrhage and early death.
  
  
  METHODS
  We studied 610 women who were 24 to 33 weeks pregnant and who were expected to deliver their infants within 24 hours. The women were randomly assigned to receive either phenobarbital (10 mg per kilogram of body weight) or placebo intravenously, followed by maintenance doses until delivery or 34 weeks of gestation. The infants born to these women underwent cranial ultrasonography to detect the presence of intracranial hemorrhage.
  
  
  RESULTS
  There were 309 women in the phenobarbital group and 301 in the placebo group. A total of 247 women (80 percent) in the phenobarbital group and 235 (78 percent) in the placebo group delivered within 24 hours after infusion of the study drug or administration of the last maintenance dose. Intracranial hemorrhage or early death occurred in 83 of the 344 infants born to the women in the phenobarbital group (24 percent) and in 74 of the 324 born to the women in the placebo group (23 percent; risk ratio for the infants in the phenobarbital group, 1.1; 95 percent confidence interval, 0.8 to 1.4). Among infants born before 34 weeks' gestation in whom ultrasonographic studies were performed, intracranial hemorrhage was diagnosed in 70 of 311 infants in the phenobarbital group (23 percent) and 64 of 279 in the placebo group (23 percent; risk ratio, 1.0; 95 percent confidence interval, 0.8 to 1.4).
  
  
  CONCLUSIONS
  Antenatal administration of phenobarbital does not decrease the risk of intracranial hemorrhage or early death in preterm infants.
authors.affiliation: Wayne State University, Detroit, MI, USA.
authors.forename: S
authors.initials: S
authors.lastname: Shankaran
authors.forename: L A
authors.initials: LA
authors.lastname: Papile
authors.forename: L L
authors.initials: LL
authors.lastname: Wright
authors.forename: R A
authors.initials: RA
authors.lastname: Ehrenkranz
authors.forename: L
authors.initials: L
authors.lastname: Mele
authors.forename: J A
authors.initials: JA
authors.lastname: Lemons
authors.forename: S B
authors.initials: SB
authors.lastname: Korones
authors.forename: D K
authors.initials: DK
authors.lastname: Stevenson
authors.forename: E F
authors.initials: EF
authors.lastname: Donovan
authors.forename: B J
authors.initials: BJ
authors.lastname: Stoll
authors.forename: A A
authors.initials: AA
authors.lastname: Fanaroff
authors.forename: W
authors.initials: W
authors.lastname: Oh
mesh_terms: D000328:Adult; D002543:Cerebral Hemorrhage / Q000000981:diagnostic imaging / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000000981:diagnostic imaging / Q000401:mortality / Q000517:prevention & control*; D016017:Odds Ratio; D010634:Phenobarbital / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D011295:Prenatal Care; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D010634:Phenobarbital